Literature DB >> 9037059

Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function.

M B Baker1, R L Riley, E R Podack, R B Levy.   

Abstract

Allogeneic bone marrow transplant recipients often exhibit a graft-versus-host-disease (GVHD)-associated immune deficiency that can be prolonged and lead to life-threatening infections. We have examined the role of donor T cell-mediated cytotoxic function in the development of GVHD-associated immune deficiency. A major histocompatibility complex-matched model of allogeneic bone marrow transplantation was employed in which lethally irradiated C3H.SW mice received a nonlethal dose of T cells from either perforin-deficient (B6-perforin 0/0), Fas-ligand (FasL)-defective (B6-gld), or normal (B6) allogeneic donor mice. T cell-depleted marrow from B6-Ly-5.1 congenic donor mice was transplanted along with the donor T cell populations to determine the effects of donor T cell-mediated cytotoxicity on engraftment. Our results demonstrate that recipients of perforin-deficient or normal allogeneic T cells exhibit profound lymphoid hypoplasia and severely reduced splenic proliferative responses to lipopolysaccharide in vitro. In contrast, GVHD-associated lymphoid hypoplasia is dramatically reduced and in vitro B cell function is intact in recipients of FasL-defective allogeneic T cells. Engraftment of myeloid and erythroid lineage cells occurs irrespective of donor T cell cytotoxic function. Although recipients of perforin-deficient or normal allogeneic T cells exhibited hematopoietic engraftment exclusively of donor origin, recipients of FasL-defective donor T cells exhibited significant mixed chimerism (Ly-5.1/Ly-5.2). Because only marrow of donor origin was transplanted, this finding suggests that Fas-mediated antirecipient cytotoxicity is required for clearance of residual hematopoietic stem cells of host origin that persist following lethal irradiation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9037059      PMCID: PMC19797          DOI: 10.1073/pnas.94.4.1366

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  Chronic graft-versus-host disease.

Authors:  K Atkinson
Journal:  Bone Marrow Transplant       Date:  1990-02       Impact factor: 5.483

2.  Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN-gamma production.

Authors:  G R Klimpel; C R Annable; M G Cleveland; T R Jerrells; J C Patterson
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

3.  Genetic nomenclature for loci controlling mouse lymphocyte antigens.

Authors:  H C Morse; F W Shen; U Hämmerling
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

4.  Suppression of B lymphocyte genesis in the bone marrow by systemic graft-versus-host reactions.

Authors:  A Xenocostas; W S Lapp; D G Osmond
Journal:  Transplantation       Date:  1987-04       Impact factor: 4.939

5.  Suppression of B-cell development as a result of selective expansion of donor T cells during the minor H antigen graft-versus-host reaction.

Authors:  B A Garvy; J M Elia; B L Hamilton; R L Riley
Journal:  Blood       Date:  1993-11-01       Impact factor: 22.113

Review 6.  The functional and histological basis for graft-versus-host-induced immunosuppression.

Authors:  W S Lapp; T Ghayur; M Mendes; M Seddik; T A Seemayer
Journal:  Immunol Rev       Date:  1985-12       Impact factor: 12.988

7.  Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro.

Authors:  J Maciejewski; C Selleri; S Anderson; N S Young
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

8.  Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression.

Authors:  D A Wall; S D Hamberg; D S Reynolds; S J Burakoff; A K Abbas; J L Ferrara
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

9.  The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice.

Authors:  M B Baker; N H Altman; E R Podack; R B Levy
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

10.  A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors.

Authors:  A Rolink; E ten Boekel; F Melchers; D T Fearon; I Krop; J Andersson
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  32 in total

1.  Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory processes.

Authors:  W J Murphy
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

2.  Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.

Authors:  T Iwasaki; T Hamano; K Saheki; T Kuroiwa; Y Kataoka; Y Takemoto; A Ogata; J Fujimoto; E Kakishita
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

3.  Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity.

Authors:  A Shustov; I Luzina; P Nguyen; J C Papadimitriou; B Handwerger; K B Elkon; C S Via
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

4.  Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.

Authors:  Antonia M S Müller; Jessica A Linderman; Mareike Florek; David Miklos; Judith A Shizuru
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

5.  Novel Scoring Criteria for the Evaluation of Ocular Graft-versus-Host Disease in a Preclinical Allogeneic Hematopoietic Stem Cell Transplantation Animal Model.

Authors:  Victor L Perez; Alexander Barsam; Stephanie Duffort; Maitee Urbieta; Henry Barreras; Casey Lightbourn; Krishna V Komanduri; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-01       Impact factor: 5.742

6.  Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice.

Authors:  Jun Li; Kenrick Semple; Woong-Kyung Suh; Chen Liu; Fangping Chen; Bruce R Blazar; Xue-Zhong Yu
Journal:  Biol Blood Marrow Transplant       Date:  2011-03-27       Impact factor: 5.742

7.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

8.  Allogeneic Th1 cells home to host bone marrow and spleen and mediate IFNγ-dependent aplasia.

Authors:  Joseph H Chewning; Weiwei Zhang; David A Randolph; C Scott Swindle; Trenton R Schoeb; Casey T Weaver
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-21       Impact factor: 5.742

9.  Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.

Authors:  Angela Mensen; Il-Kang Na; Ralf Häfer; Astrid Meerbach; Maria Schlecht; Marie-Luise Pietschmann; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-25       Impact factor: 4.553

Review 10.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.